Andrew Williams counsels clients in patent prosecution and patent litigation with a focus in the areas of biotechnology, pharmaceuticals and molecular diagnostics. His more than seventeen years of extensive experience ranges from counseling clients regarding the Biologics Price Competition and Innovation Act (“BPCIA”); patent prosecution for large, small, and university clients; and litigation before the Patent Trial and Appeal Board (“PTAB”) and in federal district court. Andrew has represented large pharmaceutical and diagnostic clients, biotechnology start-up companies and universities in fields including biological therapeutics, neuropeptides, molecular diagnostics, biosensors, reagents for diagnostics and next-generation sequencing (NGS) and food-based products.
Andrew is an active member of the IP community and has authored articles for various legal publications including Law360, Intellectual Property Magazine, Intellectual Property Today, and Expert Opinion on Therapeutic Patents and Biosimilar Developments. In particular, Andrew has written extensively on issues specific to AIA-related PTAB trials, with a particular focus on life science-related IPRs and PGRs; the emergence of BPCIA-related biosimilars and corresponding patent resolution strategies; efforts to draft legislation to curb abusive patent litigation; and ethical issues related to patent practice.
Prior to joining the firm, Andrew was a partner at McDonnell Boehnen Hulbert & Berghoff LLP. He was also a founding member and Chair of the firm’s PTAB Trials Practice Group.